Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 12 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Operating profit, profit before tax and profit attributable to owners of the parent are expected to fall below the previous forecasts due to the recognition of an impairment loss.
An impairment loss of ¥11,557 million was recorded under other operating expenses. This primarily relates to impairment of goodwill recognized upon the acquisitions of 3 consolidated subsidiaries.
| Item | Details |
|---|---|
| Net Sales | ¥500,000 million → ¥500,000 million |
| Operating profit | ¥62,000 million → ¥51,000 million（△17.7） |
| Profit attributable to owners of the parent | ¥41,000 million → ¥35,000 million（△14.6） |
| Net income per share | 65.77 yen and sen → 57.05 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 12 February 2026 |
| Previous-period results | Fiscal year ended March 2025: net sales of ¥508,643 million, operating profit of ¥87,583 million, profit before tax of ¥79,221 million, profit attributable to owners of the parent of ¥53,669 million, and basic earnings per share of ¥86.07 |
| Reason for the revision | Operating profit, profit before tax and profit attributable to owners of the parent are expected to fall below the previous forecasts due to the recognition of an impairment loss. |
| Details and amount of extraordinary loss | An impairment loss of ¥11,557 million was recorded under other operating expenses. This primarily relates to impairment of goodwill recognized upon the acquisitions of 3 consolidated subsidiaries. |
| Dividend forecast revision | No revision. Unchanged from the information announced on 14 May 2025. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the fourth quarter of the fiscal year ending March 2026, impairment testing was conducted on the goodwill recognized upon the acquisitions of Sysmex Partec GmbH, Oxford Gene Technology IP Limited and Sysmex Astrego AB. Based on the outlook for future cash flows, changes in the business environment and changes in strategy, it was determined that the recoverable amount was below the carrying amount.